Valeria Mercadante1, Siri Beier Jensen2, Derek K Smith3, Kari Bohlke4, Jessica Bauman5, Michael T Brennan6, Robert P Coppes7, Niels Jessen8, Narinder K Malhotra9, Barbara Murphy3, David I Rosenthal10, Arjan Vissink11, Jonn Wu12, Deborah P Saunders13, Douglas E Peterson14. 1. University College London and University College London Hospitals Trust, London, United Kingdom. 2. Aarhus University, Aarhus, Denmark. 3. Vanderbilt University Medical Center, Nashville, TN. 4. American Society of Clinical Oncology, Alexandria, VA. 5. Fox Chase Cancer Center, Philadelphia, PA. 6. Atrium Health's Carolinas Medical Center, Charlotte, NC. 7. University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 8. Danish Cancer Society Network for Patients with Head and Neck Cancer, Copenhagen, Denmark. 9. Meadville Medical Center, Meadville, PA. 10. The University of Texas MD Anderson Cancer Center, Houston, TX. 11. University of Groningen and University Medical Center Groningen, Groningen, the Netherlands. 12. Vancouver Cancer Centre, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada. 13. North East Cancer Centre, Northern Ontario School of Medicine, Sudbury, ON, Canada. 14. School of Dental Medicine & Neag Comprehensive Cancer Center, UConn Health, Farmington, CT.
Abstract
PURPOSE: To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020. The guideline also incorporated two previous systematic reviews conducted by MASCC/ISOO, which included studies published from 1990 through 2008. RESULTS: A total of 58 publications were identified: 46 addressed preventive interventions and 12 addressed therapeutic interventions. A majority of the evidence focused on the setting of radiation therapy for head and neck cancer. For the prevention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there is high-quality evidence for tissue-sparing radiation modalities. Evidence is weaker or insufficient for other interventions. For the management of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the use of topical mucosal lubricants, saliva substitutes, and agents that stimulate the salivary reflex. RECOMMENDATIONS: For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional information can be found at www.asco.org/supportive-care-guidelines.
PURPOSE: To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020. The guideline also incorporated two previous systematic reviews conducted by MASCC/ISOO, which included studies published from 1990 through 2008. RESULTS: A total of 58 publications were identified: 46 addressed preventive interventions and 12 addressed therapeutic interventions. A majority of the evidence focused on the setting of radiation therapy for head and neck cancer. For the prevention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there is high-quality evidence for tissue-sparing radiation modalities. Evidence is weaker or insufficient for other interventions. For the management of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the use of topical mucosal lubricants, saliva substitutes, and agents that stimulate the salivary reflex. RECOMMENDATIONS: For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional information can be found at www.asco.org/supportive-care-guidelines.
Authors: Jac A Jones; Yanin Chavarri-Guerra; Luisa Barreto Costa Corrêa; David R Dean; Joel B Epstein; Eduardo R Fregnani; Jiyeon Lee; Yuhei Matsuda; Valeria Mercadante; Ragnhild Elisabeth Monsen; Natasja J H Rajimakers; Deborah Saunders; Enrique Soto-Perez-de-Celis; Mariana S Sousa; Arghavan Tonkaboni; Arjan Vissink; Keng Soon Yeoh; Andrew N Davies Journal: Support Care Cancer Date: 2022-06-18 Impact factor: 3.603
Authors: Dirk Rades; Britta Warwas; Karsten Gerull; Ralph Pries; Anke Leichtle; Karl L Bruchhage; Samer G Hakim; Steven E Schild; Florian Cremers Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406